PharmaShots | Incisive News in 3 Shots

Subscribe Now

UCB

UCB Reports P-III Studies (BE HEARD I) & (BE HEARD II) Results of Bimekizumab for the Treatment of Hidradenitis Suppurativa

UCB Reports P-III Studies (BE HEARD I) & (BE HEARD II) Results of Bimekizumab for the Treatment of Hidradenitis Suppurativa

March 20, 2023

Iris Loew-Friedrich, CMO and Head of Development Solutions at UCB Shares her Thoughts on the Launch of New Innovators Campaign

Iris Loew-Friedrich, CMO and Head of Development Solutions at UCB Shares her Thoughts on the Launch of New Innovators Campaign

March 6, 2023

UCB Published P-III Studies (BE MOBILE 1 & 2) Results of Bimekizumab for Axial Spondyloarthritis in the Annals of the Rheumatic Diseases

UCB Published P-III Studies (BE MOBILE 1 & 2) Results of Bimekizumab for Axial Spondyloarthritis in the Annals of the Rheumatic Di...

January 19, 2023

UCB’s Fintepla (fenfluramine) Receives the CHMP Recommendation for Marketing Authorization to Treat Seizures Associated with Lennox-Gastaut syndrome

UCB’s Fintepla (fenfluramine) Receives the CHMP Recommendation for Marketing Authorization to Treat Seizures Associated with Lenno...

December 19, 2022

UCB Reports P-III Open-Label Extension Study Results of Fintepla (fenfluramine) for Lennox-Gastaut Syndrome

UCB Reports P-III Open-Label Extension Study Results of Fintepla (fenfluramine) for Lennox-Gastaut Syndrome

November 24, 2022

UCB Reports the US FDA Acceptance of NDA and EMA’s Validation of MAA for Zilucoplan to Treat Generalized Myasthenia Gravis

UCB Reports the US FDA Acceptance of NDA and EMA’s Validation of MAA for Zilucoplan to Treat Generalized Myasthenia Gravis

November 15, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us